Pancreatic cancer
Conditions
Interventions
experimental group:Endostar + Camrelizumab + Chemotherapy
control group:Chemotherapy
Sponsors
The Affiliated People's Hospital of Jiangsu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Pancreatic cancer was confirmed by pancreatic puncture, lymph node biopsy, or exfoliative cytology of peritoneal effusion, or diagnosed by imaging examination combined with laboratory examination and clinical symptom; 2. Patients with pancreatic cancer are diagnosed by surgical and pathological sections and whose recurrence and metastasis cannot be resected after radical resection; 3. All patients were proved to have at least one objectively measurable or evaluable tumor focus by imaging examination; 4. Age >= 18 years old, gender and pathological types are not limited, Karnofsky Performance Status (KPS) >= 60 points before chemotherapy, expect to receive at least two cycles of chemotherapy, estimated survival time > 3 months; 5. Blood routine, liver function, renal function, heart function, and lung function are basically normal; 6. Progesterone, adrenocortical hormone, and metabolic hormone were not treated within 3 weeks before chemotherapy; 7. No primary malignant tumors are other than the pancreas; 8. Signed informed consent and able to cooperate with treatment, willing to long-term follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with rapid progression within two cycles of chemotherapy; 2. Patients who have severe toxic reactions during chemotherapy and cannot tolerate continued chemotherapy; 3. Patients who are pregnant or lactating; 4. Patients with other primary tumors or poor compliance; 5. Diabetes or infection is not effectively controlled or other serious non-tumor factors hinder further chemotherapy; 6. Patients who want to withdraw for a variety of reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival;Tumor marker;Safety; | — |
Countries
China
Contacts
Public ContactYu Fan
The Affiliated People's Hospital of Jiangsu University
Outcome results
None listed